AstraZeneca Pharma received Import, Market permission for Durvalumab

22 Jun 2018 Evaluate

AstraZeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for durvalumab (Imfinzi). Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

8249.70 -37.65 (-0.45%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×